Publication: Missense mutations in exons 18-24 of EGFR in hepatocellular carcinoma tissues
Issued Date
2015-01-01
Resource Type
ISSN
23146141
23146133
23146133
Other identifier(s)
2-s2.0-84942246895
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
BioMed Research International. Vol.2015, (2015)
Suggested Citation
Ravat Panvichian, Anchalee Tantiwetrueangdet, Pattana Sornmayura, Surasak Leelaudomlipi Missense mutations in exons 18-24 of EGFR in hepatocellular carcinoma tissues. BioMed Research International. Vol.2015, (2015). doi:10.1155/2015/171845 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/35567
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Missense mutations in exons 18-24 of EGFR in hepatocellular carcinoma tissues
Other Contributor(s)
Abstract
© 2015 Ravat Panvichian et al. Epidermal growth factor receptor (EGFR), a transmembrane tyrosine kinase receptor, plays important roles in various cancers. In nonsmall cell lung cancer (NSCLC), EGFR mutations cluster around the ATP-binding pocket (exons 18-21) and some of these mutations activate the kinase and induce an increased sensitivity to EGFR-tyrosine kinase inhibitors. Nevertheless, data of EGFR mutations in HCC are limited. In this study, we investigated EGFR expression by immunohistochemistry and EGFR mutations (exons 18-24) by PCR cloning and sequencing. EGFR overexpression in HCC and matched nontumor tissues were detected in 13/40 (32.5%) and 10/35 (28.6%), respectively. Moreover, missense and silent mutations were detected in 13/33 (39.4%) and 11/33 (33.3%) of HCC tissues, respectively. The thirteen different missense mutations were p.L730P, p.V742I, p.K757E, p.I780T, p.N808S, p.R831C, p.V851A, p.V897A, p.S912P, p.P937L, p.T940A, p.M947V, and p.M947T. We also found already known SNP, p.Q787Q (CAG>CAA), in 13/33 (39.4%) of HCC tissues. However, no significant association was detected between EGFR mutations and EGFR overexpression, tissue, age, sex, tumor size, AFP, HBsAg, TP53, and Ki-67. Further investigation is warranted to validate the frequency and activity of these missense mutations, as well as their roles in HCC tumorigenesis and in EGFR-targeted therapy.